Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Publication year range
1.
Pharmaceuticals (Basel) ; 16(7)2023 Jul 07.
Article in English | MEDLINE | ID: mdl-37513889

ABSTRACT

We focused on the first demonstration that antiarrhythmics, particularly class II and class III antiarrhythmic and beta-blocker sotalol can induce severe occlusion/occlusion-like syndrome in rats. In this syndrome, as in similar syndromes with permanent occlusion of major vessels, peripheral and central, and other similar noxious procedures that severely disable endothelium function, the stable gastric pentadecapeptide BPC 157-collateral pathways activation, was a resolving therapy. After a high dose of sotalol (80 mg/kg intragastrically) in 180 min study, there were cause-consequence lesions in the brain (swelling, intracerebral hemorrhage), congestion in the heart, lung, liver, kidney, and gastrointestinal tract, severe bradycardia, and intracranial (superior sagittal sinus), portal and caval hypertension, and aortal hypotension, and widespread thrombosis, peripherally and centrally. Major vessels failed (congested inferior caval and superior mesenteric vein, collapsed azygos vein). BPC 157 therapy (10 µg, 10 ng/kg given intragastrically at 5 min or 90 min sotalol-time) effectively counteracted sotalol-occlusion/occlusion-like syndrome. In particular, eliminated were heart dilatation, and myocardial congestion affecting coronary veins and arteries, as well as myocardial vessels; eliminated were portal and caval hypertension, lung parenchyma congestion, venous and arterial thrombosis, attenuated aortal hypotension, and centrally, attenuated intracranial (superior sagittal sinus) hypertension, brain lesions and pronounced intracerebral hemorrhage. Further, BPC 157 eliminated and/or markedly attenuated liver, kidney, and gastrointestinal tract congestion and major veins congestion. Therefore, azygos vein activation and direct blood delivery were essential for particular BPC 157 effects. Thus, preventing such and similar events, and responding adequately when that event is at risk, strongly advocates for further BPC 157 therapy.

2.
Curr Issues Mol Biol ; 44(5): 1901-1927, 2022 Apr 27.
Article in English | MEDLINE | ID: mdl-35678659

ABSTRACT

Recently, marked therapeutic effects pertaining to the recovery of injured rat spinal cords (1 min compression injury of the sacrocaudal spinal cord (S2-Co1) resulting in tail paralysis) appeared after a single intraperitoneal administration of the stable gastric pentadecapeptide BPC 157 at 10 min post-injury. Besides the demonstrated rapid and sustained recovery (1 year), we showed the particular points of the immediate effect of the BPC 157 therapy that began rapidly after its administration, (i) soon after injury (10 min), or (ii) later (4 days), in the rats with a definitive spinal cord injury. Specifically, in counteracting spinal cord hematoma and swelling, (i) in rats that had undergone acute spinal cord injury, followed by intraperitoneal BPC 157 application at 10 min, we focused on the first 10-30 min post-injury period (assessment of gross, microscopic, and gene expression changes). Taking day 4 post-injury as the definitive injury, (ii) we focused on the immediate effects after the BPC 157 intragastric application over 20 min of the post-therapy period. Comparable long-time recovery was noted in treated rats which had definitive tail paralysis: (iii) the therapy was continuously given per orally in drinking water, beginning at day 4 after injury and lasting one month after injury. BPC 157 rats presented only discrete edema and minimal hemorrhage and increased Nos1, Nos2, and Nos3 values (30 min post-injury, (i)) or only mild hemorrhage, and only discrete vacuolation of tissue (day 4, (ii)). In the day 4-30 post-injury study (iii), BPC 157 rats rapidly presented tail function recovery, and no demyelination process (Luxol fast blue staining).

3.
Biomedicines ; 10(6)2022 Jun 01.
Article in English | MEDLINE | ID: mdl-35740321

ABSTRACT

We revealed the therapy effect of the stable gastric pentadecapeptide BPC 157 (10 µg/kg, 10 ng/kg ig or po) with specific activation of the collateral rescuing pathways, the azygos vein, on bile duct ligation in particular, and acute pancreatitis as local disturbances (i.e., improved gross and microscopy presentation, decreased amylase level). Additionally, we revealed the therapy's effect on the acute pancreatitis as vascular failure and multiorgan failure, both peripherally and centrally following "occlusion-like" syndrome, major intoxication (alcohol, lithium), maintained severe intra-abdominal hypertension, and myocardial infarction, or occlusion syndrome, and major vessel occlusion. The application-sacrifice periods were ligation times of 0-30 min, 0-5 h, 0-24 h (cured periods, early regimen) and 4.30 h-5 h, 5 h-24 h (cured periods, delayed regimen). Otherwise, bile duct-ligated rats commonly presented intracranial (superior sagittal sinus), portal and caval hypertension and aortal hypotension, gross brain swelling, hemorrhage and lesions, heart dysfunction, lung lesions, liver and kidney failure, gastrointestinal lesions, and severe arterial and venous thrombosis, peripherally and centrally. Unless antagonized with the key effect of BPC 157 regimens, reversal of the inferior caval and superior mesenteric vein congestion and reversal of the failed azygos vein activated azygos vein-recruited direct delivery to rescue the inferior-superior caval vein pathway; these were all antecedent to acute pancreatitis major lesions (i.e., acinar, fat necrosis, hemorrhage). These lesions appeared in the later period, but were markedly attenuated/eliminated (i.e., hemorrhage) in BPC 157-treated rats. To summarize, while the innate vicious cycle may be peripheral (bile duct ligation), or central (rapidly developed brain disturbances), or peripheral and central, BPC 157 resolved acute pancreatitis and its adjacent syndrome.

4.
Croat Med J ; 55(6): 562-76, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25559827

ABSTRACT

Development of cardiac allograft vasculopathy represents the major determinant of long-term survival in patients after heart transplantation. Due to graft denervation, these patients seldom present with classic symptoms of angina pectoris, and the first clinical presentations are progressive heart failure or sudden cardiac death. Although coronary angiography remains the routine technique for coronary artery disease detection, it is not sensitive enough for screening purposes. This is especially the case in the first year after transplantation when diffuse and concentric vascular changes can be easily detected only by intravascular ultrasound. The treatment of the established vasculopathy is disappointing, so the primary effort should be directed toward early prevention and diagnosis. Due to diffuse vascular changes, revascularization procedures are restricted only to a relatively small proportion of patients with favorable coronary anatomy. Percutaneous coronary intervention is preferred over surgical revascularization since it leads to better acute results and patient survival. Although there is no proven long-term advantage of drug-eluting stents for the treatment of in-stent restenosis, they are preferred over bare-metal stents. Severe vasculopathy has a poor prognosis and the only definitive treatment is retransplantation. This article reviews the present knowledge on the pathogenesis, diagnosis, treatment, and prognosis of cardiac allograft vasculopathy.


Subject(s)
Coronary Artery Disease/diagnosis , Coronary Artery Disease/therapy , Heart Transplantation , Allografts , Coronary Artery Disease/etiology , Graft Survival , Humans , Prognosis
5.
Lijec Vjesn ; 129(8-9): 260-4, 2007.
Article in Croatian | MEDLINE | ID: mdl-18198624

ABSTRACT

In Coronary Care Unit and Intensive Care Unit, Zagreb University Hospital Centre, 403 patients were hospitalized for acute myocardial infarction (AMI) in the year 2005. Majority (288) patients presented with ST-segment elevation myocardial infarction (STEMI) and 115 patients with acute myocardial infarction without ST-segment elevation (NSTEMI). In-hospital mortality of STEMI patients was 13.9% vs. 9.6% of NSTEMI group of patients. In STEMI group 202 patients underwent urgent percutaneous coronary intervention (PCI), and 86 patients in STEMI group received conservative therapy. In-hospital mortality of patients treated with primary PCI was 5.9% vs. 29.1% in the group treated conservatively. The main reason for conservative therapy was late presentation to the hospital (> 12 hours from the beginning of symptoms). Only 11 high-risk patients in NSTEMI group underwent primary PCI and 99 NSTEMI patients received conservative therapy (in-hospital mortality 10.1%). We performed totally 218 urgent PCI interventions in both groups with low in-hospital mortality of 6.1% in comparison with high mortality in conservatively treated groups of patients. The mortality in PCI group was strongly connected with unsuccessful intervention and late reperfusion. Total ischemic time (6 hours and 5 minutes), and time from hospital presentation to reperfusion -"door to balloon time" (1 hour and 25 minutes) are longer that in similar patients series, and need to be improved. Transportation time (1 hour and 40 minutes) is acceptable. In conclusion, high percentage (70.1%) of STEMI and NSTEMI patients underwent primary PCI in our institution with low perioperative mortality. This group of patients had superior in-hospital mortality when compared with conservatively treated group of patients. There is still unacceptably high percentage of patients with AMI, who came into the hospital too late for any reperfusion therapy.


Subject(s)
Hospital Mortality , Myocardial Infarction/mortality , Aged , Croatia/epidemiology , Electrocardiography , Female , Humans , Male , Middle Aged , Myocardial Infarction/diagnosis , Myocardial Infarction/therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...